CD33 and acute myeloid leukemia: Optimized dosing regimens have facilitated the reintroduction of two such drugs, including the ADC emtuzumab ozogamicin for CD33-positive acute myeloid leukemia (AML)(5), underscoring the critical need for refined dosing strategies.